TY  - GEN
AU  - Curigliano,Giuseppe
AU  - Romieu,Gilles
AU  - Campone,Mario
AU  - Dorval,Thierry
AU  - Duck,Lionel
AU  - Canon,Jean-Luc
AU  - Roemer-Becuwe,Celia
AU  - Roselli,Mario
AU  - Neciosup,Silvia
AU  - Burny,Wivine
AU  - Callegaro,Andrea
AU  - de Sousa Alves,Pedro Miguel
AU  - Louahed,Jamila
AU  - Brichard,Vincent
AU  - Lehmann,Frédéric F
TI  - A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
SN  - 1573-7217
PY  - 2016///1213
KW  - Adjuvants, Immunologic
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - Breast Neoplasms
KW  - metabolism
KW  - Disease-Free Survival
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Immunotherapy
KW  - Middle Aged
KW  - Receptor, ErbB-2
KW  - genetics
KW  - Recombinant Proteins
KW  - Trastuzumab
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1007/s10549-016-3750-y
ER  -